Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke

NCT03151993 is registered in ClinicalTrials.gov with Supergene, LLC as lead sponsor.

NCT NCT03151993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03151993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke
Lead sponsor
Supergene, LLC
Phase
Phase 3
Overall status
Completed
Start date
March 18, 2017
Completion date
June 20, 2019
Enrollment
336 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke